Actively Recruiting

Phase 3
Age: 12Years - 65Years
All Genders
NCT07348302

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Led by Inmunotek S.L. · Updated on 2026-01-16

736

Participants Needed

19

Research Sites

221 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09. The main questions it aims to answer are: Does MM09 reduce the symptoms and the need of rescue medication? What medical problems do participants have when inhaling MM09? Researchers will compare MM09 to a placebo (a look-alike substance that contains no drug) to see if MM09 works to treat rhinitis/rhinoconjunctivitis.

CONDITIONS

Official Title

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

Who Can Participate

Age: 12Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed and dated informed consent form
  • Age between 12 and 65 years at consent
  • Clinical history of intermittent or persistent moderate-to-severe rhinitis/rhinoconjunctivitis for at least 1 year caused by Dermatophagoides pteronyssinus and/or Dermatophagoides farinae
  • Positive skin prick test with a wheal diameter ≥ 5 mm for Dermatophagoides pteronyssinus and/or Dermatophagoides farinae
  • For women of childbearing age, negative serum pregnancy test and confirmed menstrual period before enrollment
  • Women of childbearing age must use highly effective contraception during the trial and 1 month after treatment
  • Ability to comply with dosage regimen
  • Ownership of a smartphone for symptom and medication logging
  • Not sensitized to other clinically relevant allergens or sensitized with specified conditions allowing inclusion
  • No sensitization to moulds, cockroach, Blomia tropicalis, or other relevant mites
  • Rhinitis/rhinoconjunctivitis symptom score ≥ 3 out of 6 for at least 10 days during baseline
  • Specific IgE against Dermatophagoides pteronyssinus and/or Dermatophagoides farinae ≥ 3.5 kU/L
Not Eligible

You will not qualify if you...

  • Previous immunotherapy to tested allergens within 5 years or any desensitization in last 2 years
  • Contraindications to allergen immunotherapy
  • Asthma with FEV1 < 80% despite treatment
  • Uncontrolled asthma or frequent/severe exacerbations
  • Severe asthma on Step 4 or 5 treatment with poor control despite adherence
  • Treatment with beta-blockers or ACE inhibitors
  • Treatment with immunosuppressive or biological drugs
  • Insufficient washout before allergen tests
  • Respiratory infection or asthma exacerbation within 4 weeks before screening
  • Chronic urticaria, severe anaphylaxis, or hereditary angioedema within 2 years
  • Contraindications for adrenaline use
  • Severe diseases unrelated to allergic rhinitis or asthma interfering with study
  • Severe, treatment-unresponsive autoimmune diseases, tumors, or immunodeficiencies
  • Inability to comply with protocol or serious mental illness
  • Known allergy to study treatment components other than study allergens
  • Nasal disease complications affecting evaluation
  • Nasal surgery within 6 months prior or planned during study
  • Oral lesions confounding safety assessment
  • Use of antihistamines or corticosteroids for reasons other than allergic rhinitis symptoms
  • Lower respiratory diseases other than asthma
  • Breastfeeding or pregnant women
  • Immediate family of investigator
  • Participation in other clinical trials within 30 days
  • History of serious systemic allergic reactions
  • Expected major life changes during study
  • Planned use of anti-mite bedding or similar during study
  • Investigator-considered inappropriate for study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 19 locations

1

Centro Médico Vitae

Nueve de Julio, Buenos Aires, Argentina, 1650

Actively Recruiting

2

Centro de Investigaciones Clínicas - Instituto de Especialidades de la Salud Rosario

Rosario, Santa Fe Province, Argentina, 2000

Actively Recruiting

3

Centro Respiratorio Infantil

Rosario, Santa Fe Province, Argentina, 2000

Actively Recruiting

4

Fundación CIDEA

Buenos Aires, Argentina, 1121

Active, Not Recruiting

5

Hospital Italiano de Buenos Aires

Buenos Aires, Argentina, 1199

Actively Recruiting

6

Centro de Educación Medica de Investigaciones Clinicas "Norberto Quirno" (CEMIC)

Buenos Aires, Argentina, 1431

Actively Recruiting

7

Beijing Tongren Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

8

The Third Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangzhou, China, 510080

Actively Recruiting

9

The First Affiliated Hospital, Sun Yat-sen University

Zhongshan, Guangzhou, China, 510080

Not Yet Recruiting

10

The Third Xiangya Hospital of Central South University

Xiangya, Hunan, China, 410013

Actively Recruiting

11

Changzhou Third People's Hospital

Changzhou, Jiangsu, China, 213003

Actively Recruiting

12

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China, 266005

Actively Recruiting

13

Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, China, 20032

Actively Recruiting

14

Tongji Hospital Tongji Medical College of HUST

Tongji, Wuhan, China, 430033

Actively Recruiting

15

Union Hospital Tongji Medical College of HUST

Huangzhou, China

Actively Recruiting

16

Unidade de Local de Saúde de Santo António, E.P.E.

Porto, Portugal, 4050-651

Not Yet Recruiting

17

ULS Lezíria- Hospital Distrital de Santarém

Santarém, Portugal, 2005-177

Not Yet Recruiting

18

Hospital IMED Benidorm

Benidorm, Alicante, Spain, 03503

Actively Recruiting

19

Hospital General Universitario Dr. Balmis

Alicante, Spain, 03010

Active, Not Recruiting

Loading map...

Research Team

R

Raquel Caballero

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df | DecenTrialz